INTERIM REPORT 1 JANUARY – 31 MARCH 2018
First quarter 2018, compared to 2017, Group
» Group net sales increased by 135% to SEK 1.1m (0.5)
» Gross order intake amounted to SEK 0.9m (0.7) an increase of 10.1%
» Order backlog amounted to SEK 0.5m (0.5)
» 34% growth in orders for Episealer® knee implants during the quarter with 39 (29) approved orders
» Loss before tax amounted to SEK –13.3m (–19.0)
» Earnings per share (weighted average) amounted to SEK –0.44 (–0.94)
Significant events during the first quarter
» Episurf Medical continued regulatory preparations and industrial partnership discussions in the US
» Episurf Medical received market approval in Israel and signed distribution agreement for the Israeli market
» Episurf Medical announced that the company is in the final stages of the development of an ankle implant
» Episurf Medical signed financing agreement of up to SEK 70m which was approved at the AGM April 9th, 2018
» Episurf Medical received another patent approval in the US related to Episurf Medical’s 3D-based damage assessment tool
» Episurf Medical presented long-term financial and operating targets
Significant events after the first quarter
» Episealer® clinical outcome was presented at the 2018 world congress of International Cartilage Repair Society (ICRS) In Macau
» Promising clinical results from use of Episealer® were presented at the annual meeting of British Association for Surgery of the Knee
» Episurf Medical’s knee products approved for marketing and sale in Spain
» Episurf Medical entered into a distribution agreement in Hong Kong and established subsidiary In the US
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 27 April 2018.
Tags: